Bioventus (BVS) Debt to Equity (2020 - 2026)

Bioventus has reported Debt to Equity for 7 years, with the latest figure at $1.44 in Q1 2026.

• For the quarter ending Q1 2026, Debt to Equity fell 16.3% year-over-year to $1.44; the trailing twelve-month figure through Mar 2026 stood at $1.44 (down 16.3% YoY), and the FY2025 full-year result was $1.29, down 27.16% from the prior year.
• Debt to Equity for Q1 2026 stood at $1.44, up from $1.29 in the prior quarter.
• The five-year high for Debt to Equity was $1.95 in Q3 2024, with the low at $0.62 in Q2 2022.
• Historically, Debt to Equity has averaged $1.51 across 5 years, with a median of $1.7 in 2025.
• Annual changes were most pronounced in 2023 — Debt to Equity jumped 198.86% — and 2025, when it fell 27.16%.
• Bioventus' Debt to Equity stood at $1.01 in 2022, then soared by 63.65% to $1.66 in 2023, then grew by 6.43% to $1.77 in 2024, then slipped by 27.16% to $1.29 in 2025, then rose by 11.94% to $1.44 in 2026.
• The last three Debt to Equity figures came in at $1.44 (Q1 2026), $1.29 (Q4 2025), and $1.94 (Q3 2025), per Business Quant data.